Catalyst Wire Dossier Catalyst Wire Dossier

MGCD0103 (mocetinostat)

mocetinostat · Mirati Therapeutics
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for MGCD0103 (mocetinostat), covering 2015-01-08 to 2015-01-08. Get the full timeline:

Most recent: Clinical Trial Update: Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma [Phase 1]

See pricing